DUBLIN – Immatics Biotechnologies GmbH is getting $30 million up front and could earn more than $1 billion in development, regulatory and commercial milestones from an immuno-oncology alliance with Amgen Inc. focused on developing two bispecific T-cells engager molecules that target intracellular tumor-associated peptide (Tumap) antigens.